Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus.
Toh, Zheng Quan;
Kosasih, Jennie;
Russell, Fiona M;
Garland, Suzanne M;
Mulholland, Edward K;
Licciardi, Paul V;
(2019)
Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus.
INFECTION AND DRUG RESISTANCE, 12.
pp. 1951-1967.
ISSN 1178-6973
DOI: https://doi.org/10.2147/IDR.S178381
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated high vaccine efficacy (>90%) against cervical, vulvar, and vaginal precancers caused by these additional types, and have shown comparable immunogenicity to the shared genotypes to quadrivalent HPV vaccine (4vHPV). Vaccine efficacy and antibody responses for 9vHPV are found to persist for at least five years while longer-term observational studies are ongoing to monitor long-term vaccine effectiveness. The implementation of 9vHPV has the potential to prevent up to 93% of cervical cancer cases, as well as a significant proportion of other HPV-related anogenital cancers. This review article summarizes the current evidence for 9vHPV in terms of vaccine efficacy against HPV infection and related anogenital precancers, safety, and immunogenicity, as well as discussing the potential impact of this vaccine on the cervical cancer burden globally.